<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2024-34-14-17</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-4122</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Изменения показателей фетального гемоглобина в крови пациентов циррозом печени с гепаторенальным синдромом 2 типа и с хронической болезнью почек</article-title><trans-title-group xml:lang="en"><trans-title>Changes in fetal hemoglobin levels in patients with liver cirrhosis with type 2 hepatorenal syndrome and chronic kidney disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5902-6796</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вознюк</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Voznyuk</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вознюк Максим Алексеевич, ассистент кафедры факультетской терапии и профессиональных болезней с курсом последипломного образования</p><p>Астрахань</p><p> </p></bio><bio xml:lang="en"><p>Voznyuk Maxim A., assistant at Dept of Faculty Therapy and Occupational Diseases with a Course of Postgraduate Education</p><p>Astrakhan</p></bio><email xlink:type="simple">tayson.91@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6725-8290</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Левитан</surname><given-names>Б. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Levitan</surname><given-names>B. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Левитан Болеслав Наумович, д.м.н., профессор, заведующий кафедрой факультетской терапии и профессиональных болезней с курсом последипломного образования</p></bio><bio xml:lang="en"><p>Levitan Boleslav N., DM Sci (habil.), professor, head of Dept of Faculty Therapy and Occupational Diseases with a Course of Postgraduate Education</p><p>Astrakhan</p></bio><email xlink:type="simple">bolev@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Астраханский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Astrakhan State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>23</day><month>01</month><year>2025</year></pub-date><volume>0</volume><issue>34</issue><issue-title>Практическая гастроэнтерология (3)</issue-title><fpage>14</fpage><lpage>17</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Вознюк М.А., Левитан Б.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Вознюк М.А., Левитан Б.Н.</copyright-holder><copyright-holder xml:lang="en">Voznyuk M.A., Levitan B.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/4122">https://www.med-alphabet.com/jour/article/view/4122</self-uri><abstract><p>Цирроз печени (ЦП) в современной популяции имеет большую распространенность и является основной причиной смертности среди всех заболеваний желудочно-кишечного тракта. Течение цирроза печени может усугубляться рядом состояний, которые делают ведение пациентов с данной патологией ещё более сложной задачей. Одним из таких состояний является гепаторенальный синдром (ГРС) 2 типа. Данное состояние является особой формой хронической болезни почек (ХБП), при которой, как считается, изменения в почках в большей степени носят функциональный и обратимый характер. Диагностика и лечение ГРС 2 типа при ЦП требуют особых подходов. Цель исследования. Установление возможных различий показателей фетального гемоглобина (HbF) у пациентов со структурным повреждением ткани почек при ХБП и нарушениями функции почек, связанными с развитием ГРС 2 типа при ЦП.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Набор участников производился среди пациентов терапевтического и гастроэнтерологического отделений ГБУЗ АО АМОКБ г. Астрахани. В исследование вошли 40 пациентов с ЦП B, C класса по Child-Pugh без признаков ГРС, 21 – с ЦП и ГРС 2 типа, 92 – с ХБП 3, 4, 5 степени, а также 43 здоровых донора в группе контроля (ГК). Анализ HbF проводился методом ракетного электрофореза в агаровом геле с додецилсульфатом натрия с использованием чистых препаратов HbF и авторских моноспецифических антисывороток к Hb F.</p></sec><sec><title>Результаты исследования</title><p>Результаты исследования. Для выявления дополнительных критериев дифференциальной диагностики ГРС 2 типа и ХБП было проведено исследование уровня HbF у данных групп пациентов, а также их сравнение по этому показателю с ЦП без ГРС и ГК. В ходе исследования было обнаружено статистически значимое снижение HbF в группе с ХБП по сравнению с больными ЦП с ГРС 2 типа, ЦП без ГРС и ГК. </p></sec><sec><title>Заключение</title><p>Заключение. Выявленные изменения позволяют использовать количественное определение уровня HbF для дифференциальной диагностики органического повреждения почек, характерного для ХБП, от нарушения функции почек при ГРС 2 типа у больных ЦП. О наличии у больного ХБП свидетельствует достоверное снижение параметров HbF по сравнению с нормой, в то время как при ЦП с ГРС 2 типа они превышают нормальные значения.</p></sec></abstract><trans-abstract xml:lang="en"><p>Liver cirrhosis (LC) is highly prevalent in the modern population and is the leading cause of death among all gastrointestinal tract diseases. The course of cirrhosis can be aggravated by a number of conditions that makes the management of patients with this pathology even more challenging. One of these conditions is hepatorenal syndrome (HRS) type 2. This condition is a special form of chronic kidney disease (CKD), in which it is believed that changes in the kidneys are largely functional and reversible. Diagnosis and treatment of HRS type 2 in LC require special approaches.</p><sec><title>The purpose of the study</title><p>The purpose of the study. To establish possible differences in fetal hemoglobin (HbF) indicators in patients with structural damage to kidney tissue in CKD and renal dysfunction associated with the development of type 2 HRS in patients with LC.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Participants were recruited among patients of the therapeutic and gastroenterological departments of the State Healthcare Institution of the Astrakhan Regional Clinical Hospital in Astrakhan. The study included 40 patients with Child-Pugh B, C LC without signs of HRS, 21 with LC and HRS type 2, 92 with CKD of stages 3, 4, 5, and 43 healthy donors in the control group (CG). HbF analysis was performed by rocket electrophoresis in agar gel with sodium dodecyl sulfate using pure HbF preparations and the author's monospecific antisera to Hb F. Results. To identify additional criteria for the differential diagnosis of HRS type 2 and CKD, a study of the HbF level was conducted in these groups of patients, as well as their comparison by this indicator LC without HRS and CG. The study revealed a statistically significant decrease in HbF in the CKD group compared to patients with LC with type 2 HRS, LC without HRS, and GC.</p></sec><sec><title>Conclusion</title><p>Conclusion. The identified changes allow using quantitative determination of the HbF level for differential diagnostics of organic kidney damage, characteristic of CKD, from renal dysfunction in type 2 HRS in patients with cirrhosis. The presence of CKD in a patient is indicated by a reliable decrease in HbF parameters, compared with the norm, while in cirrhosis with type 2 HRS they exceed normal values.</p></sec><sec><title> </title><p> </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>фетальный гемоглобин</kwd><kwd>цирроз печени</kwd><kwd>гепаторенальный синдром 2 типа</kwd><kwd>хроническая болезнь почек</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the the hepatorenal syndrome. Gastroenterol. Report. 2017; 5(2):2017:127–137. DOI: 10.1093/gastro/gox009.</mixed-citation><mixed-citation xml:lang="en">Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the the hepatorenal syndrome. Gastroenterol. Report. 2017; 5(2):2017:127–137. DOI: 10.1093/gastro/gox009.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Pose E, Piano S, Juanola A, Ginès P. Hepatorenal Syndrome in Cirrhosis. Gastroenterol. 2024;166 (4):588–604. e1. DOI: 10.1053/j.gastro.2023.11.306.</mixed-citation><mixed-citation xml:lang="en">Pose E, Piano S, Juanola A, Ginès P. Hepatorenal Syndrome in Cirrhosis. Gastroenterol. 2024;166 (4):588–604. e1. DOI: 10.1053/j.gastro.2023.11.306.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chancharoenthana W, Leelahavanichkul A. Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand? World J Gastroenterol. 2019. 25(28):3684–3703. DOI: 10.3748/wjg.v25.i28.3684.</mixed-citation><mixed-citation xml:lang="en">Chancharoenthana W, Leelahavanichkul A. Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand? World J Gastroenterol. 2019. 25(28):3684–3703. DOI: 10.3748/wjg.v25.i28.3684.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Piano S, Romano A, Di Pascoli M, Angeli P. Why and how to measure renal function in patients with liver disease. Liver Int. 2017. 37 Suppl 1:116–122. DOI: 10.1111/liv.13305.</mixed-citation><mixed-citation xml:lang="en">Piano S, Romano A, Di Pascoli M, Angeli P. Why and how to measure renal function in patients with liver disease. Liver Int. 2017. 37 Suppl 1:116–122. DOI: 10.1111/liv.13305.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 2018; 69(5):1207. DOI: 10.1016/j.jhep.2018.08.009.</mixed-citation><mixed-citation xml:lang="en">EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 2018; 69(5):1207. DOI: 10.1016/j.jhep.2018.08.009.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Belcher JM. Sanyal AJ., Peixoto AJ. et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology; 2014; 60 (2):622–32. DOI: 10.1002/hep.26980.</mixed-citation><mixed-citation xml:lang="en">Belcher JM. Sanyal AJ., Peixoto AJ. et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology; 2014; 60 (2):622–32. DOI: 10.1002/hep.26980.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Amin AA, Alabsawy EI, Jalan R, Davenport A. Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome. Semin. Nephrol. 2019; 39(1):17–30. DOI: 10.1016/j.semnephrol.2018.10.002.</mixed-citation><mixed-citation xml:lang="en">Amin AA, Alabsawy EI, Jalan R, Davenport A. Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome. Semin. Nephrol. 2019; 39(1):17–30. DOI: 10.1016/j.semnephrol.2018.10.002.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Angeli P, Garcia-Tsao G, Nadim MK., Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J. Hepatol. 2019;71(4):811–822. DOI: 10.1016/j.jhep.2019.07.002.</mixed-citation><mixed-citation xml:lang="en">Angeli P, Garcia-Tsao G, Nadim MK., Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J. Hepatol. 2019;71(4):811–822. DOI: 10.1016/j.jhep.2019.07.002.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009; 361(13):1279–90. DOI: 10.1056/NEJMra0809139.</mixed-citation><mixed-citation xml:lang="en">Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009; 361(13):1279–90. DOI: 10.1056/NEJMra0809139.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Angeli P., Garcia-Tsao, G., Nadim M. K., Parikh C. R. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J. Hepatol. 2019, 71, 811–822, https://doi.org/10.1016/j.jhep.2019.07.002.</mixed-citation><mixed-citation xml:lang="en">Angeli P., Garcia-Tsao, G., Nadim M. K., Parikh C. R. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J. Hepatol. 2019, 71, 811–822, https://doi.org/10.1016/j.jhep.2019.07.002.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Levitan B, Skvortsov V, Kasyanova Т, Vozniuk M. The diagnostic role of fetal hemoglobin and blood oxygen saturation in chronic liver diseases. Archiv euromedica. 2021;11(4):77–78. https://doi.org/10.35630/2199–885X/2021/11/4.20.</mixed-citation><mixed-citation xml:lang="en">Levitan B, Skvortsov V, Kasyanova Т, Vozniuk M. The diagnostic role of fetal hemoglobin and blood oxygen saturation in chronic liver diseases. Archiv euromedica. 2021;11(4):77–78. https://doi.org/10.35630/2199–885X/2021/11/4.20.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Вознюк М. А., Левитан Б. Н., Кривенцев Ю. А. Диагностическое значение фетального гемоглобина при хронической болезни почек. Медицинский вестник Северного Кавказа. 2024;19(3):198–201. doi: https://doi.org/10.14300/mnnc.2024.19045</mixed-citation><mixed-citation xml:lang="en">Vozniuk MA., Levitan BN., Kriventsev Yu A. Diagnostic value of fetal hemoglobin in chronic kidney disease. Medical News of North Caucasus. 2024; 19 (3): 198–201. (In Russ.). https://doi.org/10.14300/mnnc.2024.19045</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология 021; 25 (5): 10–82.doi:10.36485/1561-6274-2021-25-5-10-82.</mixed-citation><mixed-citation xml:lang="en">Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint-Petersburg). 2021;25(5):10–82. (In Russ.) doi: 10.24884/1561-6274-2021-25-5-10-82</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В. Т., Маевская М. В., Жаркова М.С и соавт. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по диагностике и лечению фиброза и цирроза печени и их осложнений. Российский журнал гастроэнтерологии, гепатологии колопроктологии. 2021;31(6):56–102. https://doi.org/10.22416/1382-4376-2021-31-6-56-102.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V. T., Maevskaya M. V., Zharkova M. S. Clinical Recommendations of the Russian Scientific Liver Society and Russian Gastroenterological Association on Diagnosis and Treatment of Liver Fibrosis, Cirrhosis and Their Complications. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(6):56–102. (In Russ.). https://doi.org/10.22416/1382-4376-2021-31-6-56-102</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
